Last reviewed · How we verify
Hypromellose Eye Drops
Hypromellose is a cellulose-based polymer that acts as an artificial tear lubricant, coating and protecting the ocular surface.
Hypromellose is a cellulose-based polymer that acts as an artificial tear lubricant, coating and protecting the ocular surface. Used for Dry eye syndrome / keratoconjunctivitis sicca, Ocular surface lubrication and protection.
At a glance
| Generic name | Hypromellose Eye Drops |
|---|---|
| Also known as | zhenshishuang |
| Sponsor | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Hypromellose (hydroxypropyl methylcellulose) is a viscous, water-soluble polymer that mimics natural tear film by forming a protective hydrophilic layer over the cornea and conjunctiva. It reduces friction between the eyelid and ocular surface, decreases evaporation of tears, and provides sustained lubrication and comfort. The polymer's mucoadhesive properties allow prolonged contact time with the eye surface.
Approved indications
- Dry eye syndrome / keratoconjunctivitis sicca
- Ocular surface lubrication and protection
Common side effects
- Transient blurred vision
- Eye irritation or discomfort
- Mild conjunctival hyperemia
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |